Sex (male vs female) | 1.608 (0.563–4.595) | 0.375 | 1.140 (0.214–6.070) | 0.878 |
Age | 0.962 (0.925–1.001) | 0.056 | 0.973 (0.926–1.021) | 0.264 |
Baseline laboratory measures | | | | |
Serum creatinine | 0.996 (0.988–1.005) | 0.408 | 1.002 (0.991–1.014) | 0.678 |
Urinary protein excretion | 0.926 (0.804–1.066) | 0.285 | 0.841 (0.663–1.065) | 0.150 |
Anti-dsDNA level | 1.002 (0.999–1.004) | 0.160 | 1.001 (0.998–1.003) | 0.636 |
C3 level | 0.976 (0.955–0.998) | 0.032 | 0.963 (0.934–0.994) | 0.021 |
Induction treatment † | | | | |
PRED + CYC, n = 64 | 1.000 | – | 1.000 | – |
PRED + MPA, n = 75 | 1.385 (0.613–3.127) | 0.433 | 3.832 (0.584–25.14) | 0.162 |
Maintenance treatment †† | | | | |
PRED + AZA, n = 85 | 1.000 | – | 1.000 | – |
PRED + MPA, n = 54 | 1.080 (0.442–2.640) | 0.866 | 0.637 (0.107–3.794) | 0.621 |
Use of antimalarial | 1.082 (0.302–3.881) | 0.903 | 0.858 (0.138–5.334) | 0.870 |
History of renal relapse | 0.500 (0.229–1.089) | 0.081 | 1.345 (0.422–4.283) | 0.616 |
Treatment era | | | | |
1983–1997 | 1.000 | – | 1.000 | – |
1998–2013 | 1.004 (0.463–2.181) | 0.991 | 0.490 (0.112–2.141) | 0.343 |